MCID: SCK001
MIFTS: 32

Sick Building Syndrome malady

Category: Respiratory diseases

Aliases & Classifications for Sick Building Syndrome

About this section

Aliases & Descriptions for Sick Building Syndrome:

Name: Sick Building Syndrome 10 12 36 2 65

Classifications:



External Ids:

Disease Ontology10 DOID:2710
SNOMED-CT59 19076009
MeSH36 D018877
UMLS65 C0037050

Summaries for Sick Building Syndrome

About this section
CDC:2 Indoor environmental quality (IEQ) refers to the quality of a building’s environment in relation to the health and wellbeing of those who occupy space within it. IEQ is determined by many factors, including lighting, air quality, and damp conditions. Workers are often concerned that they have symptoms or health conditions from exposures to contaminants in the buildings where they work. One reason for this concern is that their symptoms often get better when they are not in the building. While research has shown that some respiratory symptoms and illnesses can be associated with damp buildings, it is still unclear what measurements of indoor contaminants show that workers are at risk for disease. In most instances where a worker and his or her physician suspect that the building environment is causing a specific health condition, the information available from medical tests and tests of the environment is not sufficient to establish which contaminants are responsible. Despite uncertainty about what to measure and how to interpret what is measured, research shows that building-related symptoms are associated with building characteristics, including dampness, cleanliness, and ventilation characteristics.

MalaCards based summary: Sick Building Syndrome is related to asthma and hepatitis. An important gene associated with Sick Building Syndrome is PNPLA6 (Patatin Like Phospholipase Domain Containing 6), and among its related pathways are Adipocytokine signaling pathway and Development_Leptin signaling via JAK/STAT and MAPK cascades. Affiliated tissues include testes, eye and bone, and related mouse phenotypes are tumorigenesis and renal/urinary system.

Disease Ontology:10 An extrinsic allergic alveolitis that is characterized by a set of symptoms such as headache, fatigue, eye irritation, and breathing difficulties that affect workers in modern airtight office buildings. The disease is caused by indoor pollutants (as formaldehyde fumes, particulate matter, or microorganisms), and the symptoms tend to disappear when affected individuals leave the building.

Wikipedia:68 Sick building syndrome (SBS) is used to describe situations in which building occupants experience acute... more...

Related Diseases for Sick Building Syndrome

About this section

Graphical network of the top 20 diseases related to Sick Building Syndrome:



Diseases related to sick building syndrome

Symptoms for Sick Building Syndrome

About this section

Drugs & Therapeutics for Sick Building Syndrome

About this section

Drugs for Sick Building Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 15)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Dexamethasoneapproved, investigationalPhase 1190950-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Baycadron
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
Dexameth
Dexamethansone
 
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone acetate
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone sodium phosphate
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamethsone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
Ozurdex
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
2lenograstimPhase 11134
3Adjuvants, ImmunologicPhase 11783
4Immunologic FactorsPhase 118483
5Dexamethasone acetatePhase 119091177-87-3
6BB 1101Phase 11909
7Dexamethasone 21-phosphatePhase 11909
8
Tipranavirapproved, investigational74174484-41-465027
Synonyms:
174484-41-4
1d4y
2o4l
2o4n
2o4p
AC1L22FH
AC1Q4JPW
Aptivus
Aptivus (Boehringer Ingelheim)
Aptivus (TN)
Aptivus(TM)
CHEMBL222559
CID65027
 
D08605
DB00932
MolPort-003-850-561
N-(3-{(1R)-1-[(6R)-4-HYDROXY-2-OXO-6-PHENETHYL-6-PROPYL-5,6-DIHYDRO-2H-PYRAN-3-YL]PROPYL}PHENYL)-5-(TRIFLUOROMETHYL)-2-PYRIDINESULFONAMIDE
N-[3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-phenethyl-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide
PNU 140690
PNU-140690
PNU-140690E
TPV
Tipranavir
Tipranavir (INN)
U 140690
U-140690
UNII-ZZT404XD09
tipranavir
9
Ritonavirapproved, investigational850155213-67-5392622
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
538, ABT
A-84538
ABBOTT-84538
ABT 538
ABT 84538
ABT-538
ABT538
AC-733
AC1L94GB
AKOS000280930
Abbott 84538
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
 
DB00503
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
NSC693184
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
RIT
RTV
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
ritonavir
10Antibodies4477
11Autoantibodies117
12Immunoglobulins4477
13Antiviral Agents8071
14Anti-Retroviral Agents2794
15Anti-Infective Agents17220

Interventional clinical trials:

idNameStatusNCT IDPhase
1A Twelve Week, Open Label Extension Study in Patients With SchizophreniaCompletedNCT01566162Phase 3
2PEARL Schizophrenia MaintenanceCompletedNCT01435928Phase 3
3An Integrated Program for the Treatment of First Episode of PsychosisActive, not recruitingNCT01321177Phase 2, Phase 3
4Improved Methods of Cell Selection for Bone Marrow Transplant AlternativesRecruitingNCT00001529Phase 1
5Literacy-Adapted Psychosocial Treatments for Chronic Pain --- "Learning About Mastering/My Pain"Active, not recruitingNCT01967342
6Serum Auto-AntibodiesActive, not recruitingNCT00704626
7Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV InfectionNo longer availableNCT00062660

Search NIH Clinical Center for Sick Building Syndrome


Cochrane evidence based reviews: sick building syndrome

Genetic Tests for Sick Building Syndrome

About this section

Anatomical Context for Sick Building Syndrome

About this section

MalaCards organs/tissues related to Sick Building Syndrome:

33
Testes, Eye, Bone, Bone marrow, Endothelial, Monocytes, Liver

Animal Models for Sick Building Syndrome or affiliated genes

About this section

MGI Mouse Phenotypes related to Sick Building Syndrome:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020068.5LEP, MMP9, POMC, TRPV1
2MP:00053678.2LEP, MMP9, POMC, TRPV1
3MP:00107718.1LEP, MMP9, PNPLA6, POMC, TRPV1
4MP:00053857.9LEP, MMP9, PNPLA6, POMC, TRPV1
5MP:00053867.4ITM2B, LEP, MMP9, PNPLA6, POMC, TRPV1
6MP:00036317.3ITM2B, LEP, MMP9, PNPLA6, POMC, TRPV1

Publications for Sick Building Syndrome

About this section

Articles related to Sick Building Syndrome:

(show top 50)    (show all 201)
idTitleAuthorsYear
1
Hypoxia induced high expression of thioredoxin interacting protein (TXNIP) in non-small cell lung cancer and its prognostic effect. (25854388)
2015
2
Quercetin suppresses HeLa cells by blocking PI3K/Akt pathway. (25318886)
2014
3
A case of primary effusion lymphoma diagnosed by open cardiocentesis. (24585314)
2014
4
Two Episodes of Systemic Capillary Leak Syndrome in an 8-year-old Boy, Following Influenza A Virus Infection. (23995592)
2014
5
Genetic variation in inflammasome genes is associated with outcome in bacterial meningitis. (23053059)
2013
6
Substance use among women receiving post-rape medical care, associated post-assault concerns and current substance abuse: results from a national telephone household probability sample. (23380490)
2013
7
Response of the mitochondrial proteome of rat renal proximal convoluted tubules to chronic metabolic acidosis. (23136003)
2013
8
Cochlear abnormality in a case of Pallister-Hall syndrome. (22890695)
2012
9
Piriformis syndrome: implications of anatomical variations, diagnostic techniques, and treatment options. (22327640)
2012
10
The role of sodium hyaluronate and sodium chondroitin sulphate in the management of bladder disease. (22046200)
2011
11
Ectopic hidradenoma papilliferum on the abdomen. (21411413)
2011
12
Receptor mediated endocytosis 8 is a novel PI(3)P binding protein regulated by myotubularin-related 2. (21510942)
2011
13
An evaluation of evidence regarding application of silicone gel sheeting for the management of hypertrophic scars and keloids. (21103316)
2010
14
Easiness of use and validity testing of VS-SENSE device for detection of abnormal vaginal flora and bacterial vaginosis. (20953405)
2010
15
Visualization of clustered IgE epitopes on alpha-lactalbumin. (20466413)
2010
16
Pathomechanism of cellular infiltration in the perivascular region of several organs in SAMP1/Yit mouse. (20046021)
2009
17
Diagnosis and prediction of lung cancer through different classification techniques with tumor markers]. (19538834)
2009
18
Ets-1 mediates platelet-derived growth factor-BB-induced thrombomodulin expression in human vascular smooth muscle cells. (19091791)
2009
19
Stimulation of specific cytokines in human conjunctival epithelial cells by defensins HNP1, HBD2, and HBD3. (18806299)
2009
20
Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis. (18687167)
2008
21
The integrin-coupled signaling adaptor p130Cas suppresses Smad3 function in transforming growth factor-beta signaling. (18321991)
2008
22
Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study. (18622257)
2008
23
Effect of Mexican tea herb and pilular adina herb on concrescence of gastric mucosa in experimental gastric ulcer rats. (17609913)
2007
24
Potential roles for statins in critically ill patients. (17723082)
2007
25
Managing patients with low-risk MDS. (17139240)
2006
26
The deleterious G15498A mutation in mitochondrial DNA-encoded cytochrome b may remain clinically silent in homoplasmic carriers. (14735157)
2004
27
Inhibitory effects of bucillamine on the expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. (14975366)
2004
28
The effects of long-term diet and omega-3 fatty acid supplementation on coagulation factor VII and serum phospholipids with special emphasis on the R353Q polymorphism of the FVII gene. (15175795)
2004
29
Maxillary distraction osteogenesis in a patient with pycnodysostosis: a case report. (15278873)
2004
30
Functional promoter polymorphism in SREBP cleavage-activating protein (SCAP). (12202990)
2002
31
p53 Mutation in adenocarcinoma arising in retrorectal cyst hamartoma (tailgut cyst): report of 2 cases--an immunohistochemistry/immunoperoxidase study. (11570917)
2001
32
Cardiovascular peripheral effector mechanism in postflight orthostatic intolerance: a simulation study. (12697528)
2000
33
"Lipoblastoma-like" lipoatrophy induced by human insulin: morphological evidence for local dedifferentiation of adipocytes? (10952472)
2000
34
MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells. (11075819)
2000
35
Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux. (10600812)
1999
36
A case of Baller-Gerold syndrome. (10327256)
1999
37
Reversible phosphorylation of catalytic subunit of monovalent cation-transporting ATPases by protein kinases and phosphatases]. (10391985)
1999
38
Oxidative stress and overexpression of manganese superoxide dismutase in patients with Alzheimer's disease. (9708860)
1998
39
Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix. (9688409)
1998
40
Antegrade drilling for osteochondritis dissecans of the knee. (9195028)
1997
41
Tetrasomy 18p de novo: parental origin and different mechanisms of formation. (8840116)
1996
42
Treatment of molluscum contagiosum with oral cimetidine: clinical experience in 13 patients. (8844752)
1996
43
Bombesin stimulates the rapid activation of phospholipase A2-catalyzed phosphatidylcholine hydrolysis in Swiss 3T3 cells. (1532578)
1992
44
Unusual dentinal changes in dentinogenesis imperfecta associated with osteogenesis imperfecta. A case report. (1574308)
1992
45
Detection of hydatidiform mole in maternal serum screening programmes for Down's syndrome. (1379065)
1992
46
Extended repertoire of specific antibodies in CSF of patients with subacute sclerosing panencephalitis compared to those with multiple sclerosis: anti-bacterial antibodies are also increased. (2925841)
1989
47
CT findings in pulmonary venoocclusive disease. (6736380)
1984
48
Measurement and characterisation of human cholecystokinin-like immunoreactivity (CCK-LI) in tissues by radioimmunoassay. (6529856)
1984
49
Pityriasis rubra pilaris and and retinol-binding protein. (7194102)
1981
50
POLYNEURITIS beriberi due to a deficiency of vitamin B1. (14371243)
1955

Variations for Sick Building Syndrome

About this section

Expression for genes affiliated with Sick Building Syndrome

About this section
Search GEO for disease gene expression data for Sick Building Syndrome.

Pathways for genes affiliated with Sick Building Syndrome

About this section

Pathways related to Sick Building Syndrome according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.5LEP, POMC
2
Show member pathways
9.5LEP, POMC

GO Terms for genes affiliated with Sick Building Syndrome

About this section

Biological processes related to Sick Building Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1lipid metabolic processGO:00066299.6LEP, PNPLA6

Sources for Sick Building Syndrome

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet